NASDAQ: CGIX: DNA based diagnostics, triple digit revenue growth

 Fact Sheet  Research Report

Cancer Genetics, Inc. (CGIX) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. The Company's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPVassociated cancers. CGIX also offers a comprehensive range of non-proprietary onclogy-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Its state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have the appropriate licensure from several states including New York State. CGIX has established strong research collaborations with major cancer centers such as Mayo Clinic, Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. The Company has also established a high-profile clinical trial partnership with Gilead Sciences through its SelectOne™ program.

Find a broker to begin trading CGIX now

Investment HighlightsValue Proposition
Company Name Cancer Genetics
Market/Symbol NASDAQ: CGIX
Recent Price
Market Cap $28.85M
Avg. Daily Vol. (3m) 110,845
Price/Book N/A
Price/Cash Flow N/A
As of Sep. 29, 2016
*Source: QuoteMedia


Begin trading CGIX

 Find Broker

Investment Highlights


CGIX has groundbreaking tests in combined $10+ billion global market for hematologic, urogenital, and HPV-associated cancers.

  • Proprietary tests provide more accurate risk assessment and improved treatment options
  • Focus::Myeloid™ is a NGS-based panel for AML, MDS, and MPN that assesses 54 genes with clinical relevance for the diagnosis, prognosis, and management of myeloid cancers
  • Focus::CLL is the only NGS-based panel for CLL that offers information for patient risk stratification, disease management, and treatment selection.
  • New targeted cancer drugs for CLL require combination treatments; we believe adoption of these drugs will drive sales of Focus::CLL™ and MatBA®-CLL/SLL.
  • FHACT™ launched in U.S. in 4Q13; cervical cancer test can lower healthcare costs, save time, and provide a more accurate diagnosis. FHACT has a detection rate of up to 90%.

6M15 revenue increased 191% YoY to $8.6 million.

Awarded $6.2 million contract for a multi-year, multi-center clinical trial in CLL; this is the largest clinical trial in Company history.

Mayo Clinic JV (Oncospire Genomics) to initially focus on developing next-generation sequencing tests for lung cancer, multiple myeloma, and follicular lymphoma.

NGS-based panels for lymphoid cancers and multiple myeloma expected to launch in 2015.

Value Proposition


CGIX has 9 proprietary oncology tests (with many more in development), a growing biopharma services business that recently announced the largest clinical trial in Company history, and an international presence in some of the world’s fastest growing cancer testing markets, such as India and China. This gives the Company a complete business model that exposes it to multiple fast-growing markets. Additionally, CGIX trades at a forward EV/S multiple of 2.7x, representing a 41% discount to the median forward EV/S multiple of its peer group (4.6x), and an EV/S (FY16E) multiple of 2.6x, representing a 41% discount to the median EV/S (FY16E) multiple of 4.4x. This indicates that the stock continues to be extremely undervalued. Three independent analysts have an average target price for CGIX of $14.00, representing over 40% upside.

Cancer Genetics Latest News


Latest Investor Presentation

Latest Investor Presentation

 View Full Presentation |  Download

Ask the CEO



Meet The Board of Directors

John Pappajohn

Non-Executive Chairman

Edmund Cannon

Raju S.K. Chaganti

Andrew Pecora

Franklyn Prendergast

Panna Sharma

Chief Executive Officer

Geoffrey Harris

Director

Howard McLeod

Director

Meet The Management Team

Panna Sharma

President and Chief Executive Officer

Jane Houldsworth

Vice President of Research and Development

Lan Wang

Medical Director

Weiyi Chen

Molecular Diagnostics Director

Pal Singh-Kahlon

Cytogenetics Director

Cory Hickmon

Director of National Clinical Sales

Edward Sitar

Chief Financial Officer and Treasurer

Rob Fannon

VP of Operations

CGIX Research

Strong 2Q16 revenue growth of 67% YoY and 15% QoQ; Biopharma Services expected to drive revenue growth in 2H16 and 2017. Read More

Aug. 15, 2016

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

RedChip Direct Investment Opportunities For Private and Public Companies

Receive CGIX Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market